General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-07-29 | 2024-06 | 0 | N/A | N/A | N/A |
2024-05-15 | 2024-03 | 0 | 0.07 | N/A | N/A |
2024-04-18 | 2023-12 | 0 | N/A | N/A | N/A |
2023-11-14 | 2023-09 | 0 | 0.24 | N/A | N/A |
2023-07-31 | 2023-06 | 0 | 0.07 | N/A | N/A |
2023-05-15 | 2023-03 | 0 | -0.05 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2022-08-14 | Maxim Group | Upgrade | Buy | |
2021-05-02 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
2020-03-02 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
2017-12-03 | HC Wainwright & Co. | Upgrade | Buy | |
2015-06-28 | Cowen & Co. | Upgrade | Outperform | |
2015-04-12 | B. Riley Securities | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2006-03-28 | AUSTIN W MARXE ET AL | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Armistice Capital, LLC | 363.76K | 362.30K | 8.65% |
2023-09-29 | Ridgewood Investments LLC | 81.63K | 34.20K | 1.94% |
2023-06-29 | Virtu Financial LLC | 17.89K | 17.82K | 0.43% |
2023-06-29 | Two Sigma Securities, LLC | 12.86K | 12.81K | 0.31% |
2023-06-29 | EP Wealth Advisors, Inc. | 12.35K | 12.30K | 0.29% |
2023-06-29 | Fortress Investment Group LLC | 10.67K | 10.63K | 0.25% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 894.00 | 983.00 | 0.02% |
Split | Date |
---|---|
1 : 10 | 2022-11-23 |
0.23529 : 1 | 2013-08-23 |
0.17001 : 1 | 2007-05-14 |
$PCSA does better than this plus data should be out on monday!!
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi
-- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for β¨$1.0 billion upfront β¨-- PTC Therapeutics has option to sell rest of royalty for up to $500 β¨million; Royalty Pharma has option to buy half of rest of royalty for up β¨to $250 million β¨-- Transaction expected to enhance long-term Adjusted Cash Receipts growth β¨(non-GAAP) β¨-- Royalty Pharma to host conference call today, Thursday, October 19 at β¨9:00am EDT β¨NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.
Could be a hidden gem if newer people find it and buy solely because itβs cheap
Dont chase this and regret it later bullish!
$SPCB dont rush and expect making money in a couple of days, study the stock potentials and be patient, a good DD should rest you assured and will pay you back
$SPCB Dont chase it and wait for the surprise, this is not a daily trading one... hold and get paied
$SPCB what are the target expectations? Any clue??